TR201713954A2 - Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari - Google Patents

Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari Download PDF

Info

Publication number
TR201713954A2
TR201713954A2 TR2017/13954A TR201713954A TR201713954A2 TR 201713954 A2 TR201713954 A2 TR 201713954A2 TR 2017/13954 A TR2017/13954 A TR 2017/13954A TR 201713954 A TR201713954 A TR 201713954A TR 201713954 A2 TR201713954 A2 TR 201713954A2
Authority
TR
Turkey
Prior art keywords
tenofovir
emtrisitabin
eavirenzine
pharmaceutical combinations
pharmaceutically acceptable
Prior art date
Application number
TR2017/13954A
Other languages
English (en)
Inventor
Demi̇r Bülent
Baş Oğuz
Türkyilmaz Ali̇
Yildirim Edi̇z
Muratoğlu Yeşi̇m
Atmaca İbrahi̇m
Original Assignee
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi filed Critical Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi
Priority to TR2017/13954A priority Critical patent/TR201713954A2/tr
Priority to EP18840094.9A priority patent/EP3684341A2/en
Priority to PCT/TR2018/050508 priority patent/WO2019059868A2/en
Publication of TR201713954A2 publication Critical patent/TR201713954A2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/683Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Mevcut buluş, tenofovir veya onun farmasötik olarak kabul edilebilir bir tuzunu, emtrisitabin veya onun farmasötik olarak kabul edilebilir bir tuzunu ve efavirenz veya onun farmasötik olarak kabul edilebilir bir tuzunu içeren çentikli bir çift katmanlı tablet ile ilgilidir.
TR2017/13954A 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari TR201713954A2 (tr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
EP18840094.9A EP3684341A2 (en) 2017-09-20 2018-09-19 Pharmaceutical combinations of tenofovir, emtricitabine and efavirenz
PCT/TR2018/050508 WO2019059868A2 (en) 2017-09-20 2018-09-19 PHARMACEUTICAL COMBINATIONS OF TENOFOVIR, EMTRICITABINE AND EFAVIRENZ

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari

Publications (1)

Publication Number Publication Date
TR201713954A2 true TR201713954A2 (tr) 2019-04-22

Family

ID=65237119

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2017/13954A TR201713954A2 (tr) 2017-09-20 2017-09-20 Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari

Country Status (3)

Country Link
EP (1) EP3684341A2 (tr)
TR (1) TR201713954A2 (tr)
WO (1) WO2019059868A2 (tr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948970A (zh) * 2022-06-07 2022-08-30 安徽贝克生物制药有限公司 含依非韦伦的药物组合物及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
WO2008096369A2 (en) * 2007-02-05 2008-08-14 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy

Also Published As

Publication number Publication date
EP3684341A2 (en) 2020-07-29
WO2019059868A2 (en) 2019-03-28
WO2019059868A3 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
PH12017502431A1 (en) Pharmaceutical formulations comprising tenofovir and emtrictabine
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1124007T1 (el) Στοματικες δοσολογικες μορφες παρατεταμενης απελευθερωσης τοφασιτινιμπης
EA201792591A1 (ru) Фармацевтические препараты
CY1121999T1 (el) Φαρμακοτεχνικες μορφες συνδυασμου δαρουναβιρης
EA201390662A1 (ru) Фармацевтическая композиция, содержащая дутастерид
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
TR201916829A2 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren çi̇ft katmanli tablet formülasyonlari
CY1119446T1 (el) Φαρμακοτεχνικες μορφες δαρουναβιρης
EA202090542A1 (ru) Высококонцентрированные лекарственные формы придопидина
MX2016002560A (es) Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir.
EA202090913A1 (ru) Композиция таблеток с модифицированным высвобождением, содержащая мирабегрон
TR201914043A1 (tr) Dapagli̇flozi̇n ve metformi̇n i̇çeren efervesan tablet formülasyonlari
TR201713954A2 (tr) Tenofovir, emtrisitabin ve efavirenzin farmasötik kombinasyonlari
TR201721700A2 (tr) Saksagli̇pti̇ni̇n ağizda dağilan formülasyonlari
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин
TR201007926A1 (tr) Prasugrel tablet formülasyonları.
EA201691422A1 (ru) Перорально распадающиеся таблетированные составы мемантина
IN2013MU03370A (tr)
EA201991007A1 (ru) Твердые фармацевтические композиции на основе гидрохлорида луразидона для перорального применения
TR201721036A2 (tr) Flurbi̇profeni̇n modi̇fi̇ye salimli formülasyonlari
TR201721824A2 (tr) Li̇nagli̇pti̇n ve metformi̇n i̇çeren modi̇fi̇ye salim sağlayan kombi̇nasyon
JOP20170198A1 (ar) صيغ صيدلية تشتمل على تينوفوفير و إيمترايسيتابين